SkylineDx at the forefront of a genomic revolution
SkylineDx is dedicated to optimize therapeutic decision making through the development of molecular diagnostic tests for blood cancers and thereby improving the quality of life of blood cancer patients.
Discover more
Learn more about MMprofiler™, the lead product of SkylineDx. It is a prognostic test to determine the level of risk of a multiple myeloma patient by classifying such patient into a “high” or “standard” risk group with the use of the novel SKY92 gene signature.
Learn moreLatest news
30 Jul 2018
Groundbreaking algorithm predicts best treatment for cancer patient
Renowned scientific journal Nature Communications published July 27th, 2018 a research paper by Joske Ubels on the algorithm GESTURETM that links individual cancer patients to a specific therapeutic treatment. With this method one is able to presc...
Upcoming Events
15 Aug 2018 - 18 Aug 2018, Sydney, Australia
World Congress on the Cancers of the Skin
12 Sep 2018 - 15 Sep 2018, Hilton Americas, Houston Texas, USA
Society of Hematologic Oncology (SOHO) Annual Meeting
05 Oct 2018 - 07 Oct 2018, Mandelieu, France
European School of Haematology (ESH) 4th International Conference on Multiple Myeloma